Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
Toll-like receptors (TLRs) are expressed and play multiple functional roles in a variety of immune cell types involved in tumor immunity. There are plenty of data on the pharmacological targeting of TLR signaling using agonist molecules that boost the antitumor immune response. A recent body of rese...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/9912188 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561255964999680 |
|---|---|
| author | Saghar Pahlavanneshan Ali Sayadmanesh Hamidreza Ebrahimiyan Mohsen Basiri |
| author_facet | Saghar Pahlavanneshan Ali Sayadmanesh Hamidreza Ebrahimiyan Mohsen Basiri |
| author_sort | Saghar Pahlavanneshan |
| collection | DOAJ |
| description | Toll-like receptors (TLRs) are expressed and play multiple functional roles in a variety of immune cell types involved in tumor immunity. There are plenty of data on the pharmacological targeting of TLR signaling using agonist molecules that boost the antitumor immune response. A recent body of research has also demonstrated promising strategies for improving the cell-based immunotherapy methods by inducing TLR signaling. These strategies include systemic administration of TLR antagonist along with immune cell transfer and also genetic engineering of the immune cells using TLR signaling components to improve the function of genetically engineered immune cells such as chimeric antigen receptor-modified T cells. Here, we explore the current status of the cancer immunotherapy approaches based on manipulation of TLR signaling to provide a perspective of the underlying rationales and potential clinical applications. Altogether, reviewed publications suggest that TLRs make a potential target for the immunotherapy of cancer. |
| format | Article |
| id | doaj-art-e51dbbdc6d764ed290085c29739902c7 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-e51dbbdc6d764ed290085c29739902c72025-02-03T01:25:41ZengWileyJournal of Immunology Research2314-88612314-71562021-01-01202110.1155/2021/99121889912188Toll-Like Receptor-Based Strategies for Cancer ImmunotherapySaghar Pahlavanneshan0Ali Sayadmanesh1Hamidreza Ebrahimiyan2Mohsen Basiri3Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, IranDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, IranDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, IranToll-like receptors (TLRs) are expressed and play multiple functional roles in a variety of immune cell types involved in tumor immunity. There are plenty of data on the pharmacological targeting of TLR signaling using agonist molecules that boost the antitumor immune response. A recent body of research has also demonstrated promising strategies for improving the cell-based immunotherapy methods by inducing TLR signaling. These strategies include systemic administration of TLR antagonist along with immune cell transfer and also genetic engineering of the immune cells using TLR signaling components to improve the function of genetically engineered immune cells such as chimeric antigen receptor-modified T cells. Here, we explore the current status of the cancer immunotherapy approaches based on manipulation of TLR signaling to provide a perspective of the underlying rationales and potential clinical applications. Altogether, reviewed publications suggest that TLRs make a potential target for the immunotherapy of cancer.http://dx.doi.org/10.1155/2021/9912188 |
| spellingShingle | Saghar Pahlavanneshan Ali Sayadmanesh Hamidreza Ebrahimiyan Mohsen Basiri Toll-Like Receptor-Based Strategies for Cancer Immunotherapy Journal of Immunology Research |
| title | Toll-Like Receptor-Based Strategies for Cancer Immunotherapy |
| title_full | Toll-Like Receptor-Based Strategies for Cancer Immunotherapy |
| title_fullStr | Toll-Like Receptor-Based Strategies for Cancer Immunotherapy |
| title_full_unstemmed | Toll-Like Receptor-Based Strategies for Cancer Immunotherapy |
| title_short | Toll-Like Receptor-Based Strategies for Cancer Immunotherapy |
| title_sort | toll like receptor based strategies for cancer immunotherapy |
| url | http://dx.doi.org/10.1155/2021/9912188 |
| work_keys_str_mv | AT sagharpahlavanneshan tolllikereceptorbasedstrategiesforcancerimmunotherapy AT alisayadmanesh tolllikereceptorbasedstrategiesforcancerimmunotherapy AT hamidrezaebrahimiyan tolllikereceptorbasedstrategiesforcancerimmunotherapy AT mohsenbasiri tolllikereceptorbasedstrategiesforcancerimmunotherapy |